Craft

Repligen

Stock Price

$134.9

2024-10-29

Market Capitalization

$7.7 B

2024-10-29

Revenue

$638.8 M

FY, 2023

Repligen Summary

Company Summary

Overview
Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems. Its business is comprised of four main franchises: filtration, chromatography, process analytics, and proteins. The company serves biopharmaceutical companies, contract development, and manufacturing organizations. Filtration franchise offers covering upstream and downstream technologies. Chromatography franchise includes a number of products used in downstream purification, development, manufacturing, and quality control of biological drugs. Process analytics provides he determination of protein concentration in filtration, chromatography formulation, and fill-finish applications. Proteins franchise offers cell culture growth factor products.
Type
Public
Status
Active
Founded
1981
HQ
Waltham, MA, US | view all locations
Website
https://www.repligen.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Tony J. Hunt
  • Ralf Kuriyel

    Ralf Kuriyel, Senior Vice President, Research and Development

  • Jim Bylund
  • Christine Gebski

    Christine Gebski, Senior Vice President, Filtration and Chromatography

Operating MetricsView all

Facility Space, sq. ft.

332.9K
4.1%

FY, 2020

Trademarks (US)

12

FY, 2017

Trademarks (Foreign)

34

FY, 2017

LocationsView all

22 locations detected

  • Waltham, MA HQ

    United States

    41 Seyon St #100

  • Anaheim, CA

    United States

    121 S Old Springs Rd

  • Auburn, MA

    United States

    440 Washington St

  • Ballston Lake, NY

    United States

    1 Fairchild Square Apartment 111

  • Bridgewater Township, NJ

    United States

    685 US-202

  • Compton, CA

    United States

    18617 S Broadwick St

and 16 others

Repligen Financials

Summary Financials

Revenue (Q2, 2024)
$154.1M
Gross profit (Q2, 2024)
$76.8M
Net income (Q2, 2024)
$3.3M
Cash (Q2, 2024)
$809.1M
EBIT (Q2, 2024)
$1.5M
Enterprise value
$7.6B

Footer menu